Lanier Biotherapeutics announced that the United States Patent and Trademark Office has issued U.S. Patent 11,492,397, entitled, “Neutralizing Monoclonal Antibodies to IL-25 and Uses Thereof.”
The patent covers compositions and methods related to IL-25 binding molecules, including LNR 125, which Lanier is currently developing as a first-in-class inhibitor of the alarmin IL-25, an upstream epithelial cytokine that mediates Type 2 inflammation and is implicated in different atopic, allergic, fibrotic, viral infection and inflammatory diseases, as well as certain cancers.
“This patent covers our novel approach to treating Type 2 inflammatory disease and is a key addition to our growing intellectual property estate,” Daniel White, president and CEO of closely-held Lanier, said in a statement.
Many currently available treatments for Type 2 inflammatory disease target particular downstream cytokines and miss the opportunity to target other mediators.
Mr. White said IL-25 binding molecules, including LNR 125, target upstream cytokines called the alarmins, the very first inflammatory trigger, which enables an effect on all downstream cytokines simultaneously.
“We believe that neutralizing the activity of IL-25 can have a profound impact on improving the body’s regenerative processes that have been implicated in some of the world’s most complicated diseases, from tumor immunity to eczema,” he added.
In the case of asthma, Mr. White said targeting IL-25 with LNR 125 may “provide the treatment of asthma exacerbations caused by both allergens and viruses, meaningfully reducing viral load, which we believe cannot be accomplished with currently available therapies.”
